keyword
https://read.qxmd.com/read/38537155/giredestrant-for-estrogen-receptor-positive-her2-negative-previously-treated-advanced-breast-cancer-results-from-the-randomized-phase-ii-acelera-breast-cancer-study
#1
JOURNAL ARTICLE
Miguel Martín, Elgene Lim, Mariana Chavez-MacGregor, Aditya Bardia, Jiong Wu, Qingyuan Zhang, Zbigniew Nowecki, Felipe Melo Cruz, Rustem Safin, Sung-Bae Kim, Christian Schem, Alberto J Montero, Sarah Khan, Reeti Bandyopadhyay, Heather M Moore, Mahesh Shivhare, Monika Patre, Jorge Martinalbo, Laura Roncoroni, Pablo Diego Pérez-Moreno, Joohyuk Sohn
PURPOSE: To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor-positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455). METHODS: Post-/pre-/perimenopausal women, or men, age 18 years or older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines of systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly assigned 1:1 to giredestrant (30 mg oral once daily) or fulvestrant/aromatase inhibitor per local guidelines (+luteinizing hormone-releasing hormone agonist in pre-/perimenopausal women, and men) until disease progression/unacceptable toxicity...
March 27, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38536033/treatment-outcomes-in-older-patients-with-metastatic-breast-cancer-receiving-palbociclib-plus-an-aromatase-inhibitor-a-plain-language-summary
#2
REVIEW
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Hope S Rugo
WHAT IS THIS SUMMARY ABOUT?: This summary describes an article published in the medical journal Frontiers in Oncology in September 2023. The article reports results from a study that looked at breast cancer treatments for older patients aged 75 years or older. The study focused on a type of cancer called HR+/HER2- metastatic breast cancer. HR+/HER2- stands for hormone receptorpositive/human epidermal growth factor receptor 2-negative. This study evaluated whether older patients with this type of cancer benefited from the combination of two medicines - palbociclib and an aromatase inhibitor - compared with taking an aromatase inhibitor alone...
March 27, 2024: Future Oncology
https://read.qxmd.com/read/38535156/survival-analysis-of-male-patients-with-brain-metastases-at-initial-breast-cancer-diagnosis-over-the-last-decade
#3
JOURNAL ARTICLE
Jorge Avila, Julieta Leone, Carlos T Vallejo, José P Leone
Breast cancer in men represents approximately 1% of all breast cancer diagnoses. Among all patients with breast cancer, approximately 30% will develop brain metastases. Over the past decade, there have been multiple advances in the treatment of metastatic breast cancer; however, long-term outcomes of this presentation in male patients are lacking. We evaluated male patients with de novo stage IV breast cancer using the Surveillance, Epidemiology and End Results (SEER) database from 2010 to 2019. Overall survival (OS) was estimated using the Kaplan-Meier method and differences between groups were compared using log rank tests...
March 10, 2024: Medical Sciences: Open Access Journal
https://read.qxmd.com/read/38535080/differences-in-histological-subtypes-of-invasive-lobular-breast-carcinoma-according-to-immunohistochemical-molecular-classification
#4
JOURNAL ARTICLE
Ivan Ilić, Jana Cvetković, Ratko Ilić, Ljubiša Cvetković, Aleksandar Milićević, Stefan Todorović, Pavle Ranđelović
UNLABELLED: The technical complexity of gene expression profiling in routine practice has necessitated the use of surrogate molecular classification of breast cancer, based on immunohistochemical analyses. BACKGROUND AND OBJECTIVES: The aim of this study was to compare the differences between histological and molecular subtypes of invasive lobular carcinoma (ILC) of the breast, in order to be able to predict the behavior and prognosis of the disease, as well as to effectively determine therapy...
March 21, 2024: Diagnostics
https://read.qxmd.com/read/38534957/comparative-effectiveness-and-safety-of-trastuzumab-biosimilars-to-herceptin-for-adjuvant-treatment-of-her2-breast-cancer
#5
JOURNAL ARTICLE
Caroline Muñoz, Xiaochen Tai, Jessica Arias, Andrea Eisen, Munaza Chaudhry, Scott Gavura, Kelvin K W Chan
Background: Ontario publicly funds reference trastuzumab (Herceptin) and four biosimilar trastuzumab products for adjuvant treatment of HER2+ breast cancer. We assessed the real-world safety and effectiveness of biosimilar trastuzumab compared to Herceptin for adjuvant treatment of patients with HER2+ breast cancer. Methods: This was a population-based, retrospective study comparing the safety and effectiveness of biosimilar trastuzumab and Herceptin for neoadjuvant/adjuvant treatment of HER2+ breast cancer from 2016 to 2021...
March 21, 2024: Current Oncology
https://read.qxmd.com/read/38534931/real-world-analysis-of-the-clinical-and-economic-impact-of-the-21-gene-recurrence-score-rs-in-invasive-lobular-early-stage-breast-carcinoma-in-ireland
#6
JOURNAL ARTICLE
Lynda M McSorley, Mehala Tharmabala, Fathiya Al Rahbi, Fergus Keane, Denis Evoy, James G Geraghty, Jane Rothwell, Damian P McCartan, Megan Greally, Miriam O'Connor, Deirdre O'Mahony, Maccon Keane, Michael John Kennedy, Seamus O'Reilly, Steve J Millen, John P Crown, Catherine M Kelly, Ruth S Prichard, Cecily M Quinn, Janice M Walshe
Background: This study, using real-world data, assesses the impact of RS testing on treatment pathways and the associated economic consequences of such testing. This paper pertains to lobular breast cancer. Methods: A retrospective, observational study was undertaken between 2011 and 2019 on a cross-section of hormone receptor-positive (HR+), HER2-negative, lymph node-negative, early-stage breast cancer patients. All patients had ILC and had RS testing in Ireland. The patient population is representative of the national population...
March 1, 2024: Current Oncology
https://read.qxmd.com/read/38534929/does-pre-emptive-availability-of-predict-2-1-results-change-ordering-practices-for-oncotype-dx-a-multi-center-prospective-cohort-study
#7
JOURNAL ARTICLE
Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, Mihaela Mates, Vikaash Kumar, Mohammed F K Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark Clemons
For early-stage hormone receptor (HR)-positive and HER2-negative breast cancer, tools to estimate treatment benefit include free and publicly available algorithms (e.g., PREDICT 2.1) and expensive molecular assays (e.g., Oncotype DX). There remains a need to identify patients who de-rive the most benefit from molecular assays and where this test may be of poor value. In this multicenter prospective cohort study, we evaluated whether use of PREDICT 2.1 would impact physician decision making. For the first 6 months of the study, data on physician use of both PREDICT 2...
February 27, 2024: Current Oncology
https://read.qxmd.com/read/38534787/unveiling-the-molecular-mechanism-of-trastuzumab-resistance-in-skbr3-and-bt474-cell-lines-for-her2-positive-breast-cancer
#8
JOURNAL ARTICLE
Anna Kokot, Sachin Gadakh, Indrajit Saha, Ewa Gajda, Michał Łaźniewski, Somnath Rakshit, Kaustav Sengupta, Ayatullah Faruk Mollah, Michał Denkiewicz, Katarzyna Górczak, Jürgen Claesen, Tomasz Burzykowski, Dariusz Plewczynski
HER2-positive breast cancer is one of the most prevalent forms of cancer among women worldwide. Generally, the molecular characteristics of this breast cancer include activation of human epidermal growth factor receptor-2 (HER2) and hormone receptor activation. HER2-positive is associated with a higher death rate, which led to the development of a monoclonal antibody called trastuzumab, specifically targeting HER2. The success rate of HER2-positive breast cancer treatment has been increased; however, drug resistance remains a challenge...
March 21, 2024: Current Issues in Molecular Biology
https://read.qxmd.com/read/38532439/bispecific-aptamer-decorated-and-light-triggered-nanoparticles-targeting-tumor-and-stromal-cells-in-breast-cancer-derived-organoids-implications-for-precision-phototherapies
#9
JOURNAL ARTICLE
Simona Camorani, Alessandra Caliendo, Elena Morrone, Lisa Agnello, Matteo Martini, Monica Cantile, Margherita Cerrone, Antonella Zannetti, Massimo La Deda, Monica Fedele, Loredana Ricciardi, Laura Cerchia
BACKGROUND: Based on the established role of cancer-stroma cross-talk in tumor growth, progression and chemoresistance, targeting interactions between tumor cells and their stroma provides new therapeutic approaches. Dual-targeted nanotherapeutics selectively acting on both tumor and stromal cells may overcome the limits of tumor cell-targeting single-ligand nanomedicine due to the complexity of the tumor microenvironment. METHODS: Gold-core/silica-shell nanoparticles embedding a water-soluble iridium(III) complex as photosensitizer and luminescent probe (Iren -AuSiO2 _COOH) were efficiently decorated with amino-terminated EGFR (CL4) and PDGFRβ (Gint4...
March 26, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38531875/association-of-antibiotic-exposure-with-residual-cancer-burden-in-her2-negative-early-stage-breast-cancer
#10
JOURNAL ARTICLE
Amit A Kulkarni, Aditya Jain, Patricia I Jewett, Nidhi Desai, Laura Van 't Veer, Gillian Hirst, Douglas Yee, Anne H Blaes
Antibiotic exposure during immunotherapy (IO) has been shown to negatively affect clinical outcomes in various cancer types. The aim of this study was to evaluate whether antibiotic exposure in patients with high-risk early-stage HER2-negative breast cancer (BC) undergoing treatment with neoadjuvant pembrolizumab impacted residual cancer burden (RCB) and pathologic complete response (pCR) in the pembrolizumab-4 arm of the ISPY-2 clinical trial. Patients received pembrolizumab for four cycles concurrently with weekly paclitaxel for 12 weeks, followed by four cycles of doxorubicin plus cyclophosphamide every 2 or 3 weeks...
March 26, 2024: NPJ Breast Cancer
https://read.qxmd.com/read/38531796/dna-methylation-regulated-hoxc8-s-role-in-her2-positive-breast-cancer-function-and-its-contribution-to-herceptin-resistance
#11
JOURNAL ARTICLE
Xiaofeng Xie, Sijia Tang, Zhengyang Yu
BACKGROUND: The epidermal growth factor receptor 2 ( HER2 ) is overexpressed in 30% of breast cancers, and this overexpression is strongly correlated with a poor prognosis. Herceptin is a common treatment for HER2-positive breast cancer; however, cancer cells tend to adapt gradually to the drug, rendering it ineffective. The study revealed an association between the methylation status of the Homeobox C8 ( HOXC8 ) gene and tumor development. Therefore, it is of paramount importance to delve into the interaction between HOXC8 and HER2-positive breast cancer, along with its molecular mechanisms...
March 2024: Discovery Medicine
https://read.qxmd.com/read/38531793/characterizing-the-efficacy-and-safety-of-chemotherapy-plus-everolimus-in-her2-negative-metastatic-breast-cancer-harboring-altered-pi3k-akt-mtor
#12
JOURNAL ARTICLE
Rong Wang, Qiao-Yan Zhu, Wei-Wu Ye, Yuan Huang, Zhan-Hong Chen, Ya-Bing Zheng, Xiao Zou, Jian Wang, Dan-Lu Jiang, Xiao-Jia Wang, Zheng-Yang Xu, Wen-Ming Cao
BACKGROUND: The clinical outcomes of chemotherapy (CT) for the treatment of metastatic triple-negative (TN) and hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) have proven to be disappointing. The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway, a tumor-promoting signaling cascade frequently mutated in breast cancer (BC), has been implicated in chemoresistance...
March 2024: Discovery Medicine
https://read.qxmd.com/read/38531031/heart-failure-related-to-contemporary-breast-cancer-treatment
#13
JOURNAL ARTICLE
Megan Durkin, Neisha DeJesus
This article addresses cardiotoxicity in patients with breast cancer who are treated with anthracyclines and/or anti-human epidermal growth factor 2 (HER2) therapy, namely doxorubicin and trastuzumab. Development of concise clinical guidelines for chemotherapy-induced heart failure is ongoing. Through identification of specific risk factors and clinical predictors of cardiotoxicity, clinicians are able to better understand and define effective monitoring strategies and optimize patient care. Close cardiac monitoring is recommended for patients throughout treatment with anthracyclines and anti-HER2 therapy...
April 1, 2024: JAAPA: Official Journal of the American Academy of Physician Assistants
https://read.qxmd.com/read/38529509/overcoming-brain-derived-therapeutic-resistance-in-her2-breast-cancer-brain-metastasis
#14
Danyyl Ippolitov, Yi-Han Lin, Jeremy Spence, Aleksandra Glogowska, Thatchawan Thanasupawat, Jason Beiko, Marc R Del Bigio, Xin Xu, Amy Wang, Raul Calvo, Abhijeet Kapoor, Juan J Marugan, Mark J Henderson, Thomas Klonisch, Sabine Hombach-Klonisch
Brain metastasis of HER2+ breast cancer occurs in about 50% of all women with metastatic HER2+ breast cancer and confers poor prognosis for patients. Despite effective HER2-targeted treatments of peripheral HER2+ breast cancer with Trastuzumab +/-HER2 inhibitors, limited brain permeability renders these treatments inefficient for HER2+ breast cancer brain metastasis (BCBM). The scarcity of suitable patient-derived in-vivo models for HER2+ BCBM has compromised the study of molecular mechanisms that promote growth and therapeutic resistance in brain metastasis...
February 22, 2024: bioRxiv
https://read.qxmd.com/read/38528295/a-real-world-study-of-treatment-sequences-and-second-line-clinical-outcomes-in-patients-with-her2-positive-metastatic-breast-cancer-in-us-community-practice
#15
JOURNAL ARTICLE
Della Varghese, Giovanna I Cruz, Colden Johanson, Liz Toland, Miguel Miranda, Eleanor C Faherty, David Harland, Henry G Kaplan
PURPOSE: Standard-of-care for HER2-positive metastatic breast cancer (HER2 + mBC) patients consists of trastuzumab ± pertuzumab with chemotherapy in first-line (1L), and ado-trastuzumab emtansine (T-DM1) or the more recently approved trastuzumab deruxtecan (T-DXd) in second-line (2L). Contemporary data on treatment sequencing and real-world effectiveness is limited. This study aims to report 2L treatments and outcomes among HER2 + mBC patients in the United States (US)...
March 25, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38527731/intra-and-peritumoral-pet-radiomics-analysis-to-predict-the-pathological-response-in-breast-cancer-patients-receiving-neoadjuvant-chemotherapy
#16
JOURNAL ARTICLE
Ayşegül Aksu, Güç Zeynep Gülsüm, Kadir Alper Küçüker, Ahmet Alacacıoğlu, Bülent Turgut
OBJECTIVE: The aim of our study was to evaluate the contribution of 18Fluorine-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET) radiomic data obtained from both the tumoral and peritumoral area in predicting pathological complete response (pCR) in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy (NAC). METHODS: Female patients with a diagnosis of invasive ductal carcinoma who received NAC were evaluated retrospectively...
March 23, 2024: Revista española de medicina nuclear e imagen molecular
https://read.qxmd.com/read/38527247/pyrotinib-and-trastuzumab-plus-chemotherapy-serve-as-an-acceptable-neoadjuvant-regimen-exhibiting-good-efficacy-and-tolerance-in-her2-positive-breast-cancer-patients
#17
JOURNAL ARTICLE
Yibo Chen, Tianyi Zhang, Rui Zhang, Xuchen Cao
Objective: Pyrotinib, a new irreversible dual pan-human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase inhibitor blocking EGFR and HER2, has achieved a promising efficacy for advanced HER2-positive (HER2+ ) breast cancer. This study intended to further investigate the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2+ breast cancer treatment. Methods: Thirty-eight HER2+ breast cancer patients who received neoadjuvant pyrotinib and trastuzumab plus chemotherapy (docetaxel and carboplatin) were retrospectively reviewed...
March 25, 2024: Cancer Biotherapy & Radiopharmaceuticals
https://read.qxmd.com/read/38526689/the-effects-of-low-her2-expression-on-survival-in-patients-with-metastatic-breast-cancer-treated-with-cdk-4-6-inhibitors-a-multicenter-retrospective-study
#18
JOURNAL ARTICLE
Murad Guliyev, Gülin Alkan Şen, İlkay Gültürk, Nargiz Majidova, Goncagül Akdağ, Ali Ahadzade, Hande Turna, Nebi Serkan Demirci
PURPOSE: Endocrine therapy (ET) in combination with CDK 4/6 inhibitors (CDK 4/6i) is the standard treatment modality for hormone receptor (HR)-positive and HER2-negative metastatic breast cancer (mBC). There is uncertainty about the prognostic and predictive value of HER2-low status and whether HER2-low BC is an individual biologic subtype. In this study, we aimed to investigate the prognostic effect of HER2 expression status on survival in mBC patients treated with first-line ET plus CDK 4/6i...
March 25, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38525418/clinical-characteristics-and-prognostic-factors-of-male-breast-cancer-in-china
#19
JOURNAL ARTICLE
Han Lei, Baojie Hua, Yingying Mao, Wei Cui, Caiping Mao, Shaoxue Yang, Jiayu Li
PURPOSE: This study aimed to explore the clinical characteristics of male breast cancer (MBC) patients and the factors influencing their prognosis. METHODS: We conducted a retrospective case series analysis of 117 MBC cases who were treated at Zhejiang Cancer Hospital from 2009 to 2022. Cox proportional hazard model was used to identify prognostic factors of MBC. Nomogram was constructed based on these factors, which was further evaluated by C-index and calibration curves...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38524569/txnrd1-as-a-prognosticator-for-recurrence-metastasis-and-response-to-neoadjuvant-chemotherapy-and-radiotherapy-in-breast-cancer-patients
#20
JOURNAL ARTICLE
Raghavendra S Patwardhan, Archita Rai, Deepak Sharma, Santosh K Sandur, Sejal Patwardhan
Thioredoxin reductase 1 (Txnrd1) is known to have prognostic significance in a subset of breast cancer patients. Despite the pivotal role of Txnrd1 in regulating several cellular and physiological processes in cancer progression and metastasis, its clinical significance is largely unrecognized. Here, we undertook a retrospective comprehensive meta-analysis of 13,322 breast cancer patients from 43 independent cohorts to assess prognostic and predictive roles of Txnrd1. We observed that Txnrd1 has a positive correlation with tumor grade and size and it is over-expressed in higher-grade and larger tumors...
March 30, 2024: Heliyon
keyword
keyword
22190
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.